Antibodies to Paliperidone Haptens and Use Thereof
Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and paliperidone in a single lateral flow assay device.
1 . An isolated antibody or a binding fragment thereof, which binds to paliperidone and which:
(i) is generated in response to a conjugate of a compound of Formula I and an immunogenic carrier; or
(ii) competes for an epitope which is the same as an epitope bound by an antibody generated in response to a conjugate of a compound of Formula I and an immunogenic carrier,
wherein
L 1 is OC(O)(CH 2 ) n , or O(CH 2 ) n ;
wherein n is 2, or 3;
L 2 is NHC(O),
or absent;
L 3 is (CH 2 ) m CO 2 H, or
wherein m is 0, 1, 2, or 3; provided that m may only be 0 if L 2 is absent.
2 . The antibody of claim 1 , wherein the antibody is generated in response to a conjugate of a compound of Formula I and an immunogenic carrier.
3 . The antibody of claim 1 , wherein the antibody fragment is selected from the group of fragments consisting of Fv, F(ab′), F(ab′)2, scFv, minibody and diabody fragments.
4 . The antibody of claim 1 , wherein the antibody is a monoclonal antibody.
5 . An assay kit comprising the antibody of claim 1 .
6 . An assay device comprising the antibody of claim 1 .
7 . The assay device of claim 6 wherein the device is a lateral flow assay device.
8 . A method of producing an antibody which binds to paliperidone, the method comprising:
(i) selecting a host for antibody production; and
(ii) inoculating the host with a conjugate of a compound of Formula I and an immunogenic carrier, wherein the host produces an antibody which binds to paliperidone,
wherein
L 1 is OC(O)(CH 2 ) n , or O(CH 2 ) n ;
wherein n is 2, or 3;
L 2 is NHC(O),
or absent;
L 3 is (CH 2 ) m CO 2 H, or
wherein m is 0, 1, 2, or 3; provided that m may only be 0 if L 2 is absent.
9 . A method of producing a hybridoma cell line capable of producing a monoclonal antibody which binds to paliperidone, the method comprising:
(i) selecting a host for antibody production;
(ii) inoculating the host with a conjugate of a compound of Formula I and an immunogenic carrier;
(iii) fusing a cell line from said inoculated host with a continuously dividing cell to create a fused cell capable of producing a monoclonal antibody which binds to paliperidone; and
(iv) cloning the fused cell so as to obtain a hybridoma cell line,
wherein
L 1 is OC(O)(CH 2 ) n , or O(CH 2 ) n ;
wherein n is 2, or 3;
L 2 is NHC(O),
or absent;
L 3 is (CH 2 ) m CO 2 H, or
wherein m is 0, 1, 2, or 3; provided that m may only be 0 if L 2 is absent.
10 . A method of detecting paliperidone in a sample, the method comprising:
(i) contacting a sample with an antibody of claim 1 labeled with a detectable marker, wherein the labeled antibody and paliperidone present in the sample form a labeled complex; and
(ii) detecting the labeled complex so as to detect paliperidone in the sample.
11 . A competitive immunoassay method for detecting paliperidone in a sample, the method comprising:
(i) contacting a sample with the antibody of claim 1 , and with paliperidone or a competitive binding partner of paliperidone, wherein one of the antibody and the paliperidone or competitive binding partner thereof is labeled with a detectable marker, and wherein sample paliperidone competes with the paliperidone or competitive binding partner thereof for binding to the antibody; and
(ii) detecting the label so as to detect sample paliperidone.
12 . The method of claim 11 wherein the paliperidone or competitive binding partner thereof is labeled with the detectable marker.
13 . The method of claim 11 wherein the antibody is labeled with a detectable marker.
14 . The method of claim 11 wherein the immunoassay is performed on a lateral flow assay device and the sample is applied to the device.
15 . The method of claim 10 or 11 , further comprising detecting the presence of one or more analytes in addition to paliperidone.
16 . The method of claim 15 wherein the one or more analytes are anti-psychotic drugs other than paliperidone.
17 . The method of claim 16 wherein the anti-psychotic drugs other than paliperidone are selected from the group consisting of: risperidone, aripiprazole, quetiapine, olanzapine, and metabolites thereof.
18 . The method of claim 10 or 11 , wherein the detection of paliperidone is an indication of patient adherence with prescribed paliperidone therapy.
19 . The method of claim 10 or 11 , wherein the detection of paliperidone is used to determine whether a patient should be converted from an oral paliperidone regimen to an injectable anti-psychotic regimen.
20 . The method of claim 10 or 11 , wherein the detection of paliperidone is used to determine if the dose level or dosing interval of oral or injectable paliperidone should be increased or decreased to ensure attainment or maintenance of efficacious or safe drug levels.
21 . The method of claim 10 or 11 , wherein the detection of paliperidone is an aid in the initiation of paliperidone therapy by providing evidence of the attainment of minimum pK levels.
22 . The method of claim 10 or 11 , wherein the detection of paliperidone is used to determine bioequivalence of paliperidone in multiple formulations or from multiple sources.
23 . The method of claim 10 or 11 , wherein the detection of paliperidone is used to assess the impact of polypharmacy and potential drug-drug interactions.
24 . The method of claim 10 or 11 , wherein the detection of paliperidone is an indication that a patient should be excluded from or included into a clinical trial and is an aid in the subsequent monitoring of adherence to clinical trial medication requirements.